A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.
In 70 patients with percentages in parentheses, only 28.6% (2/7) participants had improved CT L/S in the placebo group after the trial, while 75% (6/8) participants in hydrogen/oxygen group showed alleviated hepatic steatosis. These findings add human evidence supporting molecular hydrogen's therapeutic…
Read Article